-- 太陽製藥先進研究公司（NSE：SPARC，BOM：532872）已同意以1.95億美元的價格出售其罕見兒科疾病優先審查券（PRV）。此優先審查券由美國食品藥物管理局（FDA）授予，用於批准其治療新生兒癲癇的藥物Sezaby。 根據週四提交給印度證券交易所的文件，Sezaby是一種不含苯甲醇和丙二醇的苯巴比妥鈉注射粉劑。 此次出售PRV預計將有助於該公司開發其在研產品線並加強其外部創新策略。 此交易須滿足慣例成交條件，包括相關等待期屆滿。
Related Articles
Equities
Update: -- Parex Resources Announcing Preliminary Q1 Results; Expects To generate FFO of US$114 million and FFO per share of $1.18
$PXT.TO
Equities
Parex Resources Announcing Preliminary Q1 Results; Expects To generate FFO of $114 million and FFO per share of $1.18
$PXT.TO
Research
Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.
$XPO